Prevention of Coronary Hyperreactivity in Preatherogenic Menopausal Rhesus Monkeys by Transdermal Progesterone

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 24, Issue 5, 2004, Pages 955-961

  Hermsmeyer, R Kent ^a   Mishra, Rajesh G ^a   Pavcnik, Dusan ^b   Uchida, Barry ^b   Axthelm, Michael K ^b   Stanczyk, Frank Z ^c   Burry, Kenneth A ^b   Illingworth, D Roger ^b   Kaski, Juan Carlos ^d   Nordt, Frank J ^e  

^a Dimera Incorporated   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^e Rhein Consulting Laboratories   (United States)

Author keywords

Cardiac catheterization; Coronary occlusion; Menopause; Progesterone replacement

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; CHOLESTEROL; DYE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OIL RED O STAIN; PROGESTERONE; PROSTANOID RECEPTOR; SEROTONIN; THROMBOXANE RECEPTOR; UNCLASSIFIED DRUG;

ANGIOCARDIOGRAPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; ATHEROGENESIS; ATHEROGENIC DIET; BLOOD VESSEL REACTIVITY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY BLOOD VESSEL; CREAM; FEMALE; HEART INFARCTION; IMMUNOCYTOCHEMISTRY; LIPID STORAGE; MENOPAUSE; NONHUMAN; OVARIECTOMY; PRIMATE; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; PROTEIN EXPRESSION; RHESUS MONKEY; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; WESTERN BLOTTING;

ADMINISTRATION, CUTANEOUS; ANIMALS; AORTIC DISEASES; CAROTID ARTERY DISEASES; CORONARY DISEASE; CORONARY VASOSPASM; CORONARY VESSELS; DIET, ATHEROGENIC; DRUG EVALUATION, PRECLINICAL; FEMALE; HORMONE REPLACEMENT THERAPY; LIPIDS; LIPOPROTEIN(A); MACACA MULATTA; MENOPAUSE, PREMATURE; OVARIECTOMY; PREGNANEDIOL; PROGESTERONE; SEROTONIN; VASOCONSTRICTION;

EID: 2442421179     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000126372.14332.70     Document Type: Article

References (40)

1. Oparil S. Hormones and vasoprotection (Corcoran Lecture). Hypertension. 1999;33:170-176.
2. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) research group. JAMA. 1998;280:605-613.
3. Grady D, Herrington D, Bittner V. Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N. Cardiovascular disease outcomes during 6.8 years of hormone therapy - Heart and Estrogen/progestin Replacement Study Follow-up (HERSII). JAMA-Express. 2002;288:49-57.
4. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
5. Clarkson, T. B. Effects of estrogens, progestins, and androgens on coronary vasomotion and atherosclerosis. J Reprod Med. 1998;43:741-745.
6. Hermsmeyer K, Miyagawa K, Kelley ST, Rösch J, Hall AS, Axthelm MK and Greenberg B. Reactivity based coronary vasospasm independent of atherosclerosis in rhesus monkeys. J Am Coll Cardol. 1997;29:671-680.
7. Miyagawa K, Rösch J, Stanczyk F, Hermsmeyer K. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat Med. 1997a;3:324-327.
8. 2 receptors in rhesus monkeys. Am J Physiol. 2001;281:H1498-H1507.
9. Minshall RD, Pavcnik D, Browne DL, Hermsmeyer K. Nongenomic vasodilator action of progesterone on primate coronary arteries. J Appl Physiol. 2002;92:701-708.
10. Anthony MS, Clarkson TB, Bullock BC, Wagner JD. Soy protein versus soy phytoestrogens in the prevention of diet-induced coronary artery atherosclerosis of male cynomolgus monkeys. Arterioscler Thromb Vasc Biol. 1997;17:2524-2531.
11. Adams MR, Anthony MS, Manning JM, Golden DL, Parks JS. Low-dose contraceptive estrogen-progestin and coronary artery atherosclerosis of monkeys. Obstet Gynecol. 2000;96:250-255.
12. Williams JK, Anthony MS, Herrington DM. Interactive effects of soy protein and estradiol on coronary artery reactivity in atherosclerotic, ovariectomized monkeys. Menopause. 2001;8:307-313.
13. Clarkson TB, Anthony MS, Morgan TM. Inhibition of postmenopausal atherosclerosis progression: a comparison of the effects of conjugated equine estrogens and soy phytoestrogens. J Clin Endocrinol Metab. 2001;86:41-47.
14. Hodis HN, Mack WJ, Azen SP, Lobo RA, Shoupe D, Mahrer PR, Faxon DP, Cashin-Hemphill L, Sanmarco ME, French WJ, Shook TL, Gaarder TD, Mehra AO, Rabbani R, Sevanian A, Shil AB, Torres M, Vogelbach KH, Selzer RH. Women's Estrogen-Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial Research Group. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med. 2003;349:535-545.
15. Minshall RD, Stanczyk FZ, Miyagawa K, Uchida B, Axthelm MK, Novy M, Hermsmeyer K. Ovarian steroid protection against coronary artery hyperreactivity in rhesus monkeys. J Clin Endocrinol Metab. 1998a;83:649-659.
16. Minshall RD, Miyagawa K, Chadwick CC, Novy MJ, Hermsmeyer, K. In Vitro modulation of primate coronary vascular muscle cell reactivity by ovarian steroid hormones. FASEB J. 1998b;12:1419-1429.
17. Stanczyk FZ. All progestins are not created equal. Steroids. 2003;68:879-890.
18. 2+ release mechanism of primate reactivity based coronary vasospasm. Am J Physiol. 1997b;272: H2645-H2654.
19. Bentel JM, Birrell SN, Pickering MA, Holds DJ, Horsfall DJ, Tilley WD. Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells. Mol Cell Endocrinol. 1999;154:11-20.
20. Sitruk-Ware R. Progestins and cardiovascular risk markers. Steroids. 2000;65:651-658.
21. Wakatsuki A, Okatani Y, Ikenoue N, Fukaya T. Effect of medroxyprogesterone acetate on vascular inflammatory markers in postmenopausal women receiving estrogen. Circulation. 2002;105:1436-1469.
22. Williams JK, Honoré EK, Washburn SA, Clarkson TB. Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys. J Am Coll Cardiol. 1994;24:1757-1761.
23. Levine, R. L., Chen, S. J., Durand, J., Chen, Y. F., and Oparil, S. Medroxyprogesterone attenuates estrogen-mediated inhibition of neointima formation after balloon injury of the rat carotid artery. Circulation. 1996;94:2221-2227.
24. Rosano GM, Webb CM, Chierchia S, Morgani GL, Gabraele M, Sarrel PM, de Ziegler D, Collins P. Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women. J Am Coll Cardiol. 2000;36:2154-2159.
25. Nilsen J, Brinton RD. Impact of progestins on estrugen-induced neuroprotection; synergy by progesterone and 19-norprogesterone and antagonism by medroxyprogesterone acetate. Endocrinology. 2002;143:205-212.
26. Nilsen J, Brinton RD. Divergent impact of progesterone and medroxyprogesterone acetate (Provera) on nuclear mitogen-activated protein kinase signaling. Proc Natl Acad Sci USA. 2003;100:10506-10511.
27. Adams MR, Register TC, Golden DL, Wagner JD, Williams JK. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol. 1997;17:217-221.
28. Nachman RL, Gavish D, Azrolan N, Clarkson TB. Lipoprotein(a) in diet-induced atherosclerosis in nonhuman primates. Arterioscler Thromb. 1991;11:32-38.
29. Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S. Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: Recent Advances and Future Directions. Clin Chem. 2003;49:1785-1796.
30. Lee WS, Harder JA, Yoshizumi M, Lee ME, Haber E. Progesterone inhibits arterial smooth muscle cell proliferation. Nat Med 1997;3:1005-1008.
31. Carmody BJ, Arora S, Wakefield MC, Weber M, Fox CJ, Sidawy AN. Progesterone inhibits human infragenicular arterial smooth muscle cell proliferation induced by high glucose and insulin concentrations. J Vasc Surg. 2002;36:833-838.
32. Karas RH, van Eickels M, Lydon JP, Roddy S, Kwoun M, Aronovitz M, Baur WE, Conneely O, O'Malley BW, Mendelsohn ME. A complex role for the progesterone receptor in the response to vascular injury. J Clin Invest. 2001;108:611-618.
33. Harris HA, Bapat AR, Gonder DS, Frail DE. The ligand binding profiles of estrogen receptors alpha and beta are species dependent. Steroids. 2002;67:379-384.
34. McLeod AL, Newby DE, Northridge DB, Fox KA, Uren NG. Influence of differential vascular remodeling on the coronary vasomotor response. Cardiovasc Res. 2003;59:520-526.
35. Heistad DD, Armstrong ML, Marcus ML, Piegors DJ, Mark AL. Augmented responses to vasoconstrictor stimuli in hypercholesterolemic and atherosclerotic monkeys. Circ Res. 1984;54:711-718.
36. Heistad DD, Armstrong ML, Marcus ML, Piegors DJ, Mark AL. Potentiation of vasoconstrictor responses to serotonin in the limb of atherosclerotic monkeys. J Hypertens Suppl. 1986;4:S17-S21.
37. Heistad DD, Mark AL, Marcus ML, Piegors DJ, Armstrong ML. Dietary treatment of atherosclerosis abolishes hyperresponsiveness to serotonin: implications for vasospasm. Circ Res. 1987;61:346-351.
38. Lamping KG, Piegors DJ, Benzuly KH, Armstrong ML, Heistad DD. Enhanced coronary vasoconstrictive response to serotonin subsides after removal of dietary cholesterol in atherosclerotic monkeys. Arterioscler Thromb. 1994;14:951-957.
39. Benzuly KH, Padgett RC, Kaul S, Piegors DJ, Armstrong ML, Heistad DD. Functional improvement precedes structural regression of atherosclerosis. Circulation. 1994;89:1810-1818.
40. Sobey CG, Faraci FM, Piegors DJ, Heistad DD. Effect of short-term regression of atherosclerosis on reactivity of carotid and retinal arteries. Stroke. 1996;27:927-933.